

Meeting Date: December 12, 2024
 Location: Via conference call/Teams

Agenda Item	Speaker	Recommendation	Conclusions/Recommendations	Vote
Meeting called to order			5:02PM EST	
A. Minutes from previous meetings		Review of Minutes from September 12, 2024	Minutes reviewed, approved	Yes
B. Formulary Review - New Drugs				
		Clobetasol propionate Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
		Isirivo Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
		Lazcluze Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
		Crexont Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
		Nemluvio Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
		Ohtuvayre Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
		Roflumilast Recommendation: • Move to preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
		Tiotropium Bromide Recommendation: • Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
		Combivent Respimat Recommendation: • Move to non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
		Sofdra Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
		Vorango Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
		Vafseo Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
		Zelsumvi Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
		Zorve Recommendation: • Non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
		Tacrolimus 0.03% Recommendation: • Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
		Tacrolimus 1% Recommendation: • Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
		Pimecrolimus 1% Recommendation: • Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
C. Formulary Review - PDL Modifications				
		Confirm Review of PDL Modifications Grid	Yes/No	Yes
		Recommendation: • Simlandi: Move to preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
		Recommendation: • Anjevita: Move to non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
		Recommendation: • Ustekinumab: Move to preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
		Recommendation: • luma: Move to non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
		Recommendation: • Dabigatran: Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
		Recommendation: • Savaya: Move to non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
		Recommendation: • Austedo: Move to preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
		Recommendation: • Naratriptan: Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
		Recommendation: • Zolmitriptan: Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
		Recommendation: • Eletriptan: Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
		Recommendation: • Nebivolol: Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
		Recommendation: • Pindolol: Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
		Recommendation: • Clonidine ER: Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
		Recommendation: • Guanfacine ER: Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
		Recommendation: • Atomoxetine: Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
		Recommendation: • Biktarvy: Move to preferred with Dx2Rx across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
		Recommendation: • Genvoya: Move to preferred with Dx2Rx across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
		Recommendation: • Complera: Move to preferred with Dx2Rx across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
		Recommendation: • Stribild: Move to non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0

	Recommendation: • Tadalafil (PAH): Move to preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
	Recommendation: • Calcipotriene 0.005% cream: Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
	Recommendation: • Calcipotriene 0.005% ointment: Move to preferred across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
	Recommendation: • Calcitriol 3 mcg/g ointment: Move to non-preferred with prior authorization across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
	Recommendation: • Steglatro: Move to preferred with prior authorization requiring appropriate diagnosis across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
	Recommendation: • Segluromet: Move to preferred with prior authorization requiring appropriate diagnosis across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
	Recommendation: • Dapagliflozin (Farxiga authorized generic): Move to preferred with prior authorization requiring appropriate diagnosis across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
	Recommendation: • Alogliptin: Move to preferred with prior authorization requiring appropriate diagnosis across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
	Recommendation: • Alogliptin/metformin: Move to preferred with prior authorization requiring appropriate diagnosis across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
	Recommendation: • Alogliptin/pioglitazone: Move to preferred with prior authorization requiring appropriate diagnosis across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
	Recommendation: • Meunjaro: Move to preferred with prior authorization requiring appropriate diagnosis across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
	Recommendation: • Ozempic: Move to preferred with prior authorization requiring appropriate diagnosis across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
	Recommendation: • Rybelsus: Move to preferred with prior authorization requiring appropriate diagnosis across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
	Recommendation: • Victoza (2 pen pack): Move to preferred with prior authorization requiring appropriate diagnosis across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
	Recommendation: • Liraglutide (2 pen pack): Move to preferred with prior authorization requiring appropriate diagnosis across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
	Recommendation: • Saxagliptin: Move to preferred with prior authorization requiring appropriate diagnosis across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
	Comment: [REDACTED] asked about continuation of therapy for ongoing medications when a drug gets moved from preferred with prior authorization to non-preferred with prior authorization. Is the patient now required to switch to an alternate therapy? [REDACTED] replied, it depends on the therapy/drug class. In all cases there is a pathway for that member to stay on therapy (via a prior authorization request). In certain instances we do require individuals to have another authorization to stay on current therapy when a drug moves to non-preferred with prior authorization. However, there are many instances in which we allow the existing authorizations to continue. We make the determination about continuation of ongoing therapy on a drug by drug basis.		
D. Formulary Review - New Drugs- Medical	Confirm Review of New Drugs- Medical Grid	Yes/No	Yes
	Exblifep		
	Recommendation: • Medical benefit across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
	Indeltra		
	Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
	Kisunla		
	Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
	PiaSky		
	Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
	Rytelo		
	Recommendation: • Medical benefit across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
	Ryzneuta		
	Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
	Teceltra		
	Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
	Tevimbra		
	Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
	Yimnugo		
	Recommendation: • Medical benefit with prior authorization required across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
	Zevtera		
	Recommendation: • Medical benefit across all applicable lines of business	Motion made, seconded, and carried to accept recommendation	6.0
E. Formulary Review - Drugs Evaluated Per Grid	Apply recommendations as outlined in grid	Motion made, seconded, and carried to accept recommendation	6.0
F. Clinical Guidelines	Clinical Guideline Review		
	Apply New Pharmacy Guidelines	Motion made, seconded, and carried to accept recommendation	6.0
	Continue to Apply Pharmacy Guidelines Requiring Modifications	Motion made, seconded, and carried to accept recommendation	6.0
	Remove Pharmacy Guidelines Requiring Archival	Motion made, seconded, and carried to accept recommendation	6.0
G. Annual PDL Ratification	Approve Preferred Drug Lists (PDLs) for each market, including the Wrap Plan File	Motion made, seconded, and carried to accept recommendation	
H. Quality Monitoring	Confirm Review of Quality Data	Yes/No	Yes
	DUR Review		
	Drug Recalls – 3rd Quarter 2024		
	Top 25 Drugs by Spend and Volume – 3rd Quarter 2024		
	Top 10 Drugs Requested - Approvals and Denials – 3rd Quarter 2024		
	Grievances and Appeals Data – 3rd Quarter 2024		
	Inter-Rater Reliability (IRR) – 3rd Quarter 2024		
	• Pharmacists		
	Inter-Rater Reliability (IRR) – 4th Quarter 2024		
	• Medical Directors		
Adjournment		6:47PM EST	
Proposed 2025 P&T Dates: Please mark if you have any conflicts or concerns with the following dates.			
March 6th			
June 5th			
September 11th			
December 11th			
Respectfully Submitted to the Committee,			
[REDACTED]			
UHC C&S			